Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

CompletedOBSERVATIONAL
Enrollment

204

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

August 27, 2025

Study Completion Date

August 27, 2025

Conditions
Malignant Pleural MesotheliomaUnresectable Malignant Neoplasm
Interventions
OTHER

Data collection

Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).

Trial Locations (63)

13009

IPC, Marseille

13616

CHU du Pays d'Aix, Aix-en-Provence

13915

Hôpital Nord, Marseille

14033

CHU Caen, Caen

20200

CH Bastia, Bastia

21000

CH Dijon Bourgogne, Dijon

25000

CHU Besançon, Besançon

27015

CH Eure-Seine, Évreux

29200

CHU Morvan, Brest

Clinique Pasteur, Brest

31059

Hôpital Larrey, Toulouse

33000

Clinique Bordeaux, Bordeaux

33500

CH Libourne, Libourne

33604

Hôpital Haut-Lévèque - Groupe Hospitalier SUD, Pessac

35000

CHU Ponchailloux, Rennes

Clinique Saint Grégoire, Rennes

35400

CH de Saint Malo, St-Malo

37044

CHRU Bretonneau, Tours

42100

Hôpital privé de la Loire, Saint-Etienne

44600

Clinique de l'Estuaire, Saint-Nazaire

44805

Insititut de Cancerologie de l'Ouest, Saint-Herblain

49033

CHU Angers, Angers

50102

CH du Cotentin, Cherbourg

56100

Hôpital du Scorff, Lorient

58000

CH Nevers, Nevers

59000

CHU Lille, Lille

63000

CHU Hôpital Montpied, Clermont-Ferrand

Unicancer, Clermont-Ferrand

63660

Clinique Ambroise Paré, Beuvry

64100

CH Bayonne, Bayonne

68000

Hôpital Louis Pasteur, Colmar

69100

CH Villeurbanne, Villeurbanne

69373

Centre Léon Bérard, Lyon

69400

CH Villefranche, Villefranche-sur-Saône

69500

Hôpital Louis Pradel, Bron

72000

CH du Mans, Le Mans

74374

CH Annecy Genevois, Pringy

75005

Institut Curie, Paris

75014

Hôpital Cochin, Paris

75018

Hôpital Bichat, Paris

75651

Hôpital La Pitié-Salpêtrière, Paris

75674

GH Paris Site St Joseph, Paris

76031

Hôpital Charles Nicolle, Rouen

76083

GH Le Havre, Le Havre

76091

Les Hôpitaux Universitaires de Strasbourg, Strasbourg

81013

CH Albi, Albi

83056

CHITS Toulon Sainte Musse, Toulon

83800

HIA St Anne, Toulon

84000

CH Avignon, Avignon

85000

CHD les Oudaries, La Roche-sur-Yon

86021

CHU La Mileterie, Poitiers

91160

CH de Longjumeau, Longjumeau

91640

CH Bligny, Bligny

92100

Hôpital Ambroise Paré, Boulogne-Billancourt

94160

HIA Begin, Saint-Mandé

94250

Clinique Gentilly, Gentilly

95010

CH Argenteuil, Argenteuil

06400

CH Cannes, Cannes

06250

CAC Mougins, Mougins

06000

Clinique Saint Georges, Nice

06149

Centre Antoine Lacassagne, Nice

02900

CH Cornouaille, Quimper

02321

CH St Quentin, Saint-Quentin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Groupe Francais De Pneumo-Cancerologie

OTHER

NCT05308966 - Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) | Biotech Hunter | Biotech Hunter